EPO and Glucose intolerance: Given that EPO treatment inhibits the NF-κB, ERK and JNK activation, and TNF-α and IL-6 production in animal models of hepatic injury [25]–[28], we hypothesize that EPO may also inhibit the HFD-induced chronic inflammation, contributing to the improvement of glucose intolerance and insulin resistance.